Maxence Frere’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
ContactOut Insights • AI Generated
Maxence Frere serves as an iOS Developer at Ad Scientiam, a French computer software firm specializing in clinical digital biomarkers for continuous disease monitoring. He completed his technical studies at EPITECH, the European Institute of Technology, which underpins his mobile application development expertise. In his current role, he builds iOS solutions that empower patients to track illness progression in real time and support healthcare professionals with individualized care insights.
BEST APPROACH TO REACH Maxence Frere
Contact him directly via LinkedIn by sending a tailored message that highlights how your product or opportunity complements Ad Scientiam’s mission to develop digital biomarkers for serious and disabling diseases.
iOS Developer at Ad Scientiam in January 2020 - Present
iOS Developer at Dunasys ingénierie in July 2019 - January 2020
Développeur iOS - Communications Sécurisées 🔐🔏 - Objective C at ERCOM in October 2017 - June 2019
Développeur Logiciel - Télématique 🚙 - C++ at Dunasys ingénierie in January 2017 - September 2017
Développeur Mobile - Réalité Virtuelle - Unity5 et C++ at Groupe SII in September 2015 - August 2016
Développeur Logiciel - Test et Qualité - JAVA ☕️ at Mobile Devices Ingenierie in September 2013 - July 2014
Développeur Web at Storylation in September 2012 - December 2012
EPITECH - European Institute of Technology, Master’s Degree, July 2026
Chung-Ang University, July 2026
At the heart of Ad Scientiam's project is a conviction: measuring and monitoring the evolution of serious and disabling diseases on a continuous basis and in real life is essential for better management. We make visible these evolutions, until now undetectable, through the design and clinical validation of digital biomarkers. This scientific and technological challenge should enable each patient to be an active participant in their own illness and allow healthcare professionals to offer more individualized and therefore more efficient care. Ad Scientiam thus participates in the development of future treatments and in reducing the societal and economic impact of diseases. Hospital institutions such as the Brain Institute (ICM) and pharmaceutical companies such as Biogen, Janssen, Roche, Pfizer, Vertex and Novartis have already trusted us. In 2018, Ad Scientiam launched MSCopilot®, the first and only CE-marked software medical device for the self-assessment of multiple sclerosis patients. New devices are currently being validated in neuroscience, rare diseases and mental disorders.
Discover more about Ad ScientiamLead developpeur iOS chez Ad Scientiam
Lead Developpeur iOS at Ad Scientiam
(April 2019 – Present)
PharmD, MSc ESCP, Director, Medical Affairs & Market Access Innovation - MedTech
Medical Affairs and Market Access Innovation Director at Ad Scientiam
(Mar 2025 – Present)
President at Ad Scientiam
Chief Executive Officer at Ad Scientiam
(Nov 2021 – Present)
Product Owner
Product Manager at Ad Scientiam
(Sep 2025 – Present)
CSO - Digital Biomarkers & Digital Health Technology
Chief Scientific Officer at Ad Scientiam
(Feb 2025 – Present)
Consultant - Product Owner at MEOTEC
Scoping produit sur une nouvelle pathologie rare :
- Benchmarking et identification des opportunités
- Définition de l'intended use
- Identification des biomarkers pertinents pour le suivi de l'évolution des symptômes par les professionnels de santé
- Etude et POC d'év...
What is Maxence Frere email address?
Email Maxence Frere at [email protected] and [email protected]. This email is the most updated Maxence Frere's email found in 2026.
How to contact Maxence Frere?
To contact Maxence Frere send an email to [email protected] or [email protected]. (updated on November 15, 2025)
What company does Maxence Frere work for?
Maxence Frere works for Ad Scientiam.
What is Maxence Frere's role at Ad Scientiam?
Maxence Frere is iOS Developer
What industry does Maxence Frere work in?
Maxence Frere works in the Computer Software industry.
